LONDON, April 10, 2013 /PRNewswire/ --
Verona Pharma plc
("Verona Pharma" or the "Company")
Verona Pharma plc (VRP: London Stock Exchange) ("Verona Pharma", or the "Company"), the biotechnology company focused on developing novel treatments for chronic respiratory diseases, today presented its preliminary results to financial analysts in London. The presentation given is on the Company website.
Please visit http://www.veronapharma.com.
Notes to Editors
About Verona Pharma plc
Verona Pharma is developing first-in-class drugs to treat respiratory disease, such as COPD, asthma and chronic, severe cough. The Company has three drug programmes, two of which are in Phase II. The lead programme, RPL554, is an innovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties. VRP700 is an innovative product for suppressing chronic, severe cough in patients with underlying lung disease. In its third programme, Verona Pharma is investigating novel anti-inflammatory molecules, called NAIPs, for a wide range of respiratory and inflammatory diseases.
For further information please contact:
Verona Pharma plc Tel: +44(0)20-7863-3300
Clive Page, Chairman
Jan-Anders Karlsson, CEO
WH Ireland Limited Tel: +44(0)20-7220-1666
FTI Consulting Tel: +44(0)20-7831-3113
SOURCE Verona Pharma PLC